JP6991585B2 - メニン阻害剤としてのピペリジン - Google Patents

メニン阻害剤としてのピペリジン Download PDF

Info

Publication number
JP6991585B2
JP6991585B2 JP2018557418A JP2018557418A JP6991585B2 JP 6991585 B2 JP6991585 B2 JP 6991585B2 JP 2018557418 A JP2018557418 A JP 2018557418A JP 2018557418 A JP2018557418 A JP 2018557418A JP 6991585 B2 JP6991585 B2 JP 6991585B2
Authority
JP
Japan
Prior art keywords
group
alkyl
optionally substituted
pharmaceutically acceptable
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018557418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514950A (ja
JP2019514950A5 (enExample
Inventor
シャオメン ワン
アンジェロ アギラー
ケ チャン
シリン スー
ティアンフェン スー
デンジル ベルナード
リュー フアン
Original Assignee
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン filed Critical ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン
Publication of JP2019514950A publication Critical patent/JP2019514950A/ja
Publication of JP2019514950A5 publication Critical patent/JP2019514950A5/ja
Application granted granted Critical
Publication of JP6991585B2 publication Critical patent/JP6991585B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018557418A 2016-05-02 2017-05-02 メニン阻害剤としてのピペリジン Expired - Fee Related JP6991585B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330350P 2016-05-02 2016-05-02
US62/330,350 2016-05-02
PCT/US2017/030577 WO2017192543A1 (en) 2016-05-02 2017-05-02 Piperidines as menin inhibitors

Publications (3)

Publication Number Publication Date
JP2019514950A JP2019514950A (ja) 2019-06-06
JP2019514950A5 JP2019514950A5 (enExample) 2020-06-18
JP6991585B2 true JP6991585B2 (ja) 2022-01-12

Family

ID=58699299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018557418A Expired - Fee Related JP6991585B2 (ja) 2016-05-02 2017-05-02 メニン阻害剤としてのピペリジン

Country Status (13)

Country Link
US (2) US10899738B2 (enExample)
EP (1) EP3452461B1 (enExample)
JP (1) JP6991585B2 (enExample)
KR (1) KR20190015275A (enExample)
CN (1) CN109415337B (enExample)
AU (1) AU2017259436B2 (enExample)
BR (1) BR112018072570A2 (enExample)
CA (1) CA3022868A1 (enExample)
ES (1) ES2899936T3 (enExample)
IL (2) IL262697B (enExample)
MX (1) MX384087B (enExample)
SG (1) SG11201809714TA (enExample)
WO (1) WO2017192543A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020515571A (ja) * 2017-03-31 2020-05-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 共有結合性メニン阻害剤としてのピペリジン

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
EP3302057A4 (en) 2015-06-04 2018-11-21 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
KR102419524B1 (ko) 2016-03-16 2022-07-08 쿠라 온콜로지, 인크. 메닌-mll의 가교된 이환식 억제제 및 사용 방법
EP3429591B1 (en) 2016-03-16 2023-03-15 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
US10899738B2 (en) 2016-05-02 2021-01-26 The Regents Of The University Of Michigan Piperidines as menin inhibitors
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
ES2872003T3 (es) 2016-09-14 2021-11-02 Janssen Pharmaceutica Nv Inhibidores espirobicíclicos de la interacción de menina-MLL
CN109715634B (zh) 2016-09-14 2022-09-27 詹森药业有限公司 Menin-mll相互作用的稠合二环抑制剂
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
KR102513564B1 (ko) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 아제판 억제제
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
TW202003465A (zh) * 2018-03-30 2020-01-16 美國密西根州立大學 作為共價menin抑制劑之六氫吡啶化合物
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
WO2020069027A1 (en) * 2018-09-26 2020-04-02 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
JP2022502409A (ja) * 2018-10-03 2022-01-11 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン 低分子メニン阻害剤
AU2019417833B2 (en) * 2018-12-31 2024-11-07 Biomea Fusion, Inc. Irreversible inhibitors of menin-MLL interaction
EP3906029A4 (en) 2018-12-31 2022-09-21 Biomea Fusion, LLC MENIN-MLL INTERACTION INHIBITORS
TW202126636A (zh) 2019-09-30 2021-07-16 美商阿吉歐斯製藥公司 作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物
MX2022007652A (es) 2019-12-19 2022-09-23 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal.
TW202204334A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
TW202204333A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
MX2023013174A (es) 2021-05-08 2023-11-30 Janssen Pharmaceutica Nv Derivados espiro sustituidos.
JP2024518425A (ja) 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換スピロ誘導体
KR20240006625A (ko) * 2021-05-12 2024-01-15 신닥스 파마슈티컬스, 인크. 암 치료를 위한 조합물
AU2022286467A1 (en) 2021-06-01 2024-01-25 Janssen Pharmaceutica Nv SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES
BR112023025436A2 (pt) 2021-06-03 2024-02-27 Janssen Pharmaceutica Nv Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
JP2024525145A (ja) 2021-06-17 2024-07-10 ヤンセン ファーマシューティカ エヌ．ベー． がんなどの疾患の治療のための（ｒ）－ｎ－エチル－５－フルオロ－ｎ－イソプロピル－２－（（５－（２－（６－（（２－メトキシエチル）（メチル）アミノ）－２－メチルヘキサン－３－イル）－２，６－ジアザスピロ［３．４］オクタン－６－イル）－１，２，４－トリアジン－６－イル）オキシ）ベンズアミドベシル酸塩
JP2024531170A (ja) 2021-08-11 2024-08-29 バイオメア フュージョン，インコーポレイテッド 真性糖尿病に対するメニン－ｍｌｌ相互作用の共有結合性阻害剤
JP2024534014A (ja) 2021-08-20 2024-09-18 バイオメア フュージョン，インコーポレイテッド 癌の処置のための不可逆的メニン－ＭＬＬ阻害剤、Ｎ－［４－［４－（４－モルホリニル）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－イル］フェニル］－４－［［３（Ｒ）－［（１－オキソ－２－プロペン－１－イル）アミノ］－１－ピペリジニル］メチル］－２－ピリジンカルボキサミドの結晶形態
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
EP4525873A1 (en) * 2022-05-17 2025-03-26 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
TW202430528A (zh) 2023-01-18 2024-08-01 美商拜歐米富士恩股份有限公司 Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑
CN120987784A (zh) * 2025-10-23 2025-11-21 辽宁鸿港化工有限公司 一种对甲氧基苄胺及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014200479A1 (en) 2013-06-12 2014-12-18 The Regents Of The University Of Michigan Menin-mll inhibitors and methods of use thereof
US20140371239A1 (en) 2013-06-12 2014-12-18 The Regents Of The University Of Michigan Menin-mll inhibitors and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
AU7450898A (en) 1997-05-28 1998-12-30 Tokyo Tanabe Company Limited Indole compounds
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
WO2008070303A2 (en) 2006-10-19 2008-06-12 The University Of Chicago Therapeutics to inhibit mll-menin interaction for treating leukemia
CA2773131C (en) 2009-09-04 2015-07-14 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
US8946197B2 (en) 2009-11-16 2015-02-03 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
IN2013MN02014A (enExample) 2011-05-09 2015-06-12 Forma Tm Llc
BR112015022602A2 (pt) 2013-03-13 2017-07-18 Univ Michigan Regents composições compreendendo compostos de tienopirimidina e tienopiridina e métodos de uso dos mesmos
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
EP3302057A4 (en) 2015-06-04 2018-11-21 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
RU2018126774A (ru) 2015-12-22 2020-01-23 Витэ Фармасьютикалз, Инк. Ингибиторы менин-mll взаимодействия
EP3429591B1 (en) 2016-03-16 2023-03-15 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
KR102419524B1 (ko) 2016-03-16 2022-07-08 쿠라 온콜로지, 인크. 메닌-mll의 가교된 이환식 억제제 및 사용 방법
US10899738B2 (en) 2016-05-02 2021-01-26 The Regents Of The University Of Michigan Piperidines as menin inhibitors
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
AU2017326006B2 (en) 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
KR20190133224A (ko) 2017-03-31 2019-12-02 더 리젠츠 오브 더 유니버시티 오브 미시간 공유 메닌 억제제로서의 피페리딘
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
WO2020069027A1 (en) 2018-09-26 2020-04-02 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014200479A1 (en) 2013-06-12 2014-12-18 The Regents Of The University Of Michigan Menin-mll inhibitors and methods of use thereof
US20140371239A1 (en) 2013-06-12 2014-12-18 The Regents Of The University Of Michigan Menin-mll inhibitors and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BURM BRIGITTE E A; GREMMEN CHRISTIAAN; WANNER MARTIN J; ET AL，SYNTHESIS OF NEW BRIDGED TETRAHYDRO-Β-CARBOLINES AND SPIRO-FUSED QUINUCLIDINES，TETRAHEDRON，2001年，VOL:57, NR:10，PAGE(S):2039 - 2049，http://dx.doi.org/10.1016/S0040-4020(01)00023-0
HE S; ET AL，HIGH-AFFINITY SMALL MOLECULE INHIBITORS OF THE MENIN-MIXED LINEAGE LEUKEMIA (MLL) 以下備考，JOURNAL OF MEDICINAL CHEMISTRY，2014年01月28日，VOL:57，PAGE(S):1543 - 1556，http://dx.doi.org/10.1021/jm401868d，INTERACTION CLOSELY MIMIC A NATURAL PROTEIN-PROTEIN INTERACTION
KITA Y; ET AL，ENHANCING EFFECTS OF SALT FORMATION ON CATALYTIC ACTIVITY AND ENANTIOSELECTIVITY FOR 以下備考，CHEMISTRY - A EUROPEAN JOURNAL，2014年11月28日，VOL:21，PAGE(S):1915 - 1927，ASYMETRIC HYDROGENATION OF ISOQUINOLINIUM SALTS BY DINUCLEAR HALIDE-BRIDGED IRIDIUM 以下省略
PITTA B R; ET AL，METALATED NITRILE AND ENOLATE CHLORINATIONS，ORGANIC LETTERS，2010年05月18日，VOL:12, NR:12，PAGE(S):2810 - 2813，http://dx.doi.org/10.1021/ol100897y
PRAT L; ET AL，SYNTHESIS OF N-METHYL-4-PYRIDYL-1,2,3,4-TETRAHYDROISOQUINOLINES VIA A PICTET-SPENGLER CYCLISATION，JOURNAL OF HETEROCYCLIC CHEMISTRY，2000年07月，VOL:37，PAGE(S):767 - 771，https://onlinelibrary.wiley.com/doi/abs/10.1002/jhet.5570370417
SENTER T; ET AL，PROGRESS TOWARDS SMALL MOLECULE MENIN-MIXED LINEAGE LEUKEMIA (MLL) INTERACTION INHIBITORS 以下備考，BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS，2015年04月25日，VOL:25，PAGE(S):2720 - 2725，http://dx.doi.org/10.1016/j.bmcl.2015.04.026，WITH IN VIVO UTILITY

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020515571A (ja) * 2017-03-31 2020-05-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 共有結合性メニン阻害剤としてのピペリジン

Also Published As

Publication number Publication date
US20190152947A1 (en) 2019-05-23
AU2017259436B2 (en) 2021-08-26
US20210198237A1 (en) 2021-07-01
ES2899936T3 (es) 2022-03-15
IL262697A (en) 2018-12-31
EP3452461B1 (en) 2021-09-08
MX384087B (es) 2025-03-14
MX2018013433A (es) 2019-07-18
KR20190015275A (ko) 2019-02-13
US10899738B2 (en) 2021-01-26
CN109415337B (zh) 2022-01-18
JP2019514950A (ja) 2019-06-06
IL281182A (en) 2021-04-29
CA3022868A1 (en) 2017-11-09
IL262697B (en) 2021-04-29
AU2017259436A1 (en) 2018-12-20
EP3452461A1 (en) 2019-03-13
CN109415337A (zh) 2019-03-01
WO2017192543A1 (en) 2017-11-09
SG11201809714TA (en) 2018-11-29
BR112018072570A2 (pt) 2019-02-19

Similar Documents

Publication Publication Date Title
JP6991585B2 (ja) メニン阻害剤としてのピペリジン
JP7037500B2 (ja) Ｍｄｍ２タンパク質分解剤
JP7072519B2 (ja) Ｂｅｔタンパク質分解剤
CN110062759B (zh) 作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬
JP2020515571A (ja) 共有結合性メニン阻害剤としてのピペリジン
JP2021519785A (ja) 共有結合性メニン阻害剤としてのピペリジン化合物
CN112119080B (zh) 作为lsd-1抑制剂的咪唑并[4,5-c]吡啶化合物
KR20210072787A (ko) 저분자 메닌 억제제
CN120712252A (zh) 包含sos1抑制剂和抗癌药物的用于治疗癌症的药物组合物
HK40006016B (en) Piperidines as menin inhibitors
HK40006016A (en) Piperidines as menin inhibitors
HK40041770B (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40041770A (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181128

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20191218

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211201

R150 Certificate of patent or registration of utility model

Ref document number: 6991585

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees